NCT02097056View on ClinicalTrials.gov

Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Alzheimer's Disease
Interventions
DRUG

Donepezil HCL

Donepezil HCl 23 mg once daily, just before bed, for 24 weeks

Trial Locations (13)

Unknown

Ansan

Buchoen

Seongnam-si

Jinju

Iksan

Hwasun

Busan

Daegu

Daejeon

Incheon

Jeju City

Seoul

Chungju

All Listed Sponsors
lead

Eisai Korea Inc.

INDUSTRY

NCT02097056 - Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease | Biotech Hunter | Biotech Hunter